Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: We need a 5th Grader, not a Forensic Accountant! - Simple Math escapes PTSC

I don't disagree with your points.

However, I would say that if there was a consistent metric that the market could analyze, predict and interpret the results, I do think it would help PTSC's share price, even if the license fees were relatively small ($1M -$5M range). My point is that with the way PTSC communicates or allows others to communicate for them, there is no way to know what to believe from them, and thus there is no follow through with the PPS.

There was $11M in fees collected last FY. Was that for just 3 licenses that were announced (Dresser, Cummins and Stryker), or was that for the 11 that is intimated by comparing the running license count numbers included in the PR's?

It's a big difference between nearly $4M per license vs $1M per license. When the company contradicts itself and is abundantly opaque in the info it provides, it inspires no confidence or reason to invest by the market.

Share
New Message
Please login to post a reply